Table 2 Promoter methylation markers in colorectal carcinomas compared with clinicopathological features
| Â | GDNF | HAND2 | SLC35F3 | SNAP91 | SORCS1 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
M | U | M | U | M | U | M | U | M | U | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Tumors | ||||||||||
 Number | 17 (40.5) | 25 (59.5) | 11 (26.2) | 31 (73.8) | 15 (35.7) | 27 (64.3) | 19 (45.2) | 23 (54.8) | 17 (40.5) | 25 (59.5) |
Sex | ||||||||||
 Male | 11 (64.7) | 17 (68.0) | 8 (72.7) | 20 (64.5) | 10 (66.7) | 18 (66.7) | 11 (57.9) | 17 (73.9) | 10 (58.9) | 18 (72.0) |
 Female | 6 (35.3) | 8 (32.0) | 3 (27.3) | 11 (35.5) | 5 (33.3) | 9 (33.3) | 8 (42.1) | 6 (26.1) | 7 (41.1) | 7 (28.0) |
 P value | 0.824 | 0.620 | 1.000 | 0.273 | 0.374 |  |  |  |  |  |
Cancer stage | ||||||||||
 Stage I | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 Stage II | 5 (31.3) | 2 (8.0) | 2 (20.0) | 5 (16.1) | 3 (21.4) | 4 (14.8) | 6 (33.3) | 1 (4.3) | 4 (25.0) | 3 (12.0) |
 Stage III | 8 (50.0) | 16 (64.0) | 5 (50.0) | 19 (61.3) | 7 (50.0) | 17 (63.0) | 8 (44.5) | 16 (69.6) | 8 (50.0) | 16 (64.0) |
 Stage IV | 3 (18.7) | 7 (28.0) | 3 (30.0) | 7 (22.6) | 4 (28.6) | 6 (22.2) | 4 (22.2) | 6 (26.1) | 4 (25.0) | 6 (24.0) |
 P value | 0.153 | 0.818 | 0.721 | 0.047 | 0.523 |  |  |  |  |  |
Tumor location | ||||||||||
 Proximal | 0 (0.0) | 14 (60.9) | 1 (9.1) | 13 (46.4) | 0 (0.0) | 14 (56.0) | 0 (0.0) | 14 (66.7) | 0 (0.0) | 14 (60.9) |
 Distal | 16 (100.0) | 9 (39.1) | 10 (90.9) | 15 (53.6) | 14 (100.0) | 11 (44.0) | 18 (100.0) | 7 (33.3) | 16 (100.0) | 9 (39.1) |
 P value | 0.000 | 0.029 | 0.000 | 0.000 | 0.000 |  |  |  |  |  |
Age (years) | ||||||||||
 Mean age (± SD) | 71 (± 7.6) | 70 (± 12.2) | 73 (± 7.7) | 70 (± 11.2) | 70 (± 9.6) | 71 (± 11.1) | 70 (± 9.0) | 71 (± 11.7) | 70 (± 9.0) | 71 (± 11.5) |
 P value | 0.927 | 0.333 | 0.812 | 0.663 | 0.885 |  |  |  |  |  |